This week in the PNAS Early Edition, researchers at the Washington University School of Medicine show that LRP6 silencing in breast cancer cells reduces Wnt signaling, cell proliferation, and tumor growth. Their results suggest that an LRP6 antagonist, Mesd, is a promising antitumor agent and potential therapeutic target for breast cancer subtypes with Wnt activation at the cell surface.